These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 19318489)

  • 1. Cdc7 kinase is a predictor of survival and a novel therapeutic target in epithelial ovarian carcinoma.
    Kulkarni AA; Kingsbury SR; Tudzarova S; Hong HK; Loddo M; Rashid M; Rodriguez-Acebes S; Prevost AT; Ledermann JA; Stoeber K; Williams GH
    Clin Cancer Res; 2009 Apr; 15(7):2417-25. PubMed ID: 19318489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subcellular localization of activated leukocyte cell adhesion molecule is a molecular predictor of survival in ovarian carcinoma patients.
    Mezzanzanica D; Fabbi M; Bagnoli M; Staurengo S; Losa M; Balladore E; Alberti P; Lusa L; Ditto A; Ferrini S; Pierotti MA; Barbareschi M; Pilotti S; Canevari S
    Clin Cancer Res; 2008 Mar; 14(6):1726-33. PubMed ID: 18347173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased Cdc7 expression is a marker of oral squamous cell carcinoma and overexpression of Cdc7 contributes to the resistance to DNA-damaging agents.
    Cheng AN; Jiang SS; Fan CC; Lo YK; Kuo CY; Chen CH; Liu YL; Lee CC; Chen WS; Huang TS; Wang TY; Lee AY
    Cancer Lett; 2013 Sep; 337(2):218-25. PubMed ID: 23684929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cdc7 inhibition reveals a p53-dependent replication checkpoint that is defective in cancer cells.
    Montagnoli A; Tenca P; Sola F; Carpani D; Brotherton D; Albanese C; Santocanale C
    Cancer Res; 2004 Oct; 64(19):7110-6. PubMed ID: 15466207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cdc7 as a potential new target for cancer therapy.
    Ito S; Taniyami C; Arai N; Masai H
    Drug News Perspect; 2008 Nov; 21(9):481-8. PubMed ID: 19180266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of the hyaluronan receptor, CD44S, in epithelial ovarian cancer is an independent predictor of survival.
    Kayastha S; Freedman AN; Piver MS; Mukkamalla J; Romero-Guittierez M; Werness BA
    Clin Cancer Res; 1999 May; 5(5):1073-6. PubMed ID: 10353740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting DNA replication before it starts: Cdc7 as a therapeutic target in p53-mutant breast cancers.
    Rodriguez-Acebes S; Proctor I; Loddo M; Wollenschlaeger A; Rashid M; Falzon M; Prevost AT; Sainsbury R; Stoeber K; Williams GH
    Am J Pathol; 2010 Oct; 177(4):2034-45. PubMed ID: 20724597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting cell division cycle 7 kinase: a new approach for cancer therapy.
    Montagnoli A; Moll J; Colotta F
    Clin Cancer Res; 2010 Sep; 16(18):4503-8. PubMed ID: 20647475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression analysis and RNA localization of PAI-RBP1 (SERBP1) in epithelial ovarian cancer: association with tumor progression.
    Koensgen D; Mustea A; Klaman I; Sun P; Zafrakas M; Lichtenegger W; Denkert C; Dahl E; Sehouli J
    Gynecol Oncol; 2007 Nov; 107(2):266-73. PubMed ID: 17698176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity.
    Montagnoli A; Valsasina B; Croci V; Menichincheri M; Rainoldi S; Marchesi V; Tibolla M; Tenca P; Brotherton D; Albanese C; Patton V; Alzani R; Ciavolella A; Sola F; Molinari A; Volpi D; Avanzi N; Fiorentini F; Cattoni M; Healy S; Ballinari D; Pesenti E; Isacchi A; Moll J; Bensimon A; Vanotti E; Santocanale C
    Nat Chem Biol; 2008 Jun; 4(6):357-65. PubMed ID: 18469809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lysophosphatidic acid acyltransferase-beta (LPAAT-beta) is highly expressed in advanced ovarian cancer and is associated with aggressive histology and poor survival.
    Diefenbach CS; Soslow RA; Iasonos A; Linkov I; Hedvat C; Bonham L; Singer J; Barakat RR; Aghajanian C; Dupont J
    Cancer; 2006 Oct; 107(7):1511-9. PubMed ID: 16944535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrative genomic analysis of phosphatidylinositol 3'-kinase family identifies PIK3R3 as a potential therapeutic target in epithelial ovarian cancer.
    Zhang L; Huang J; Yang N; Greshock J; Liang S; Hasegawa K; Giannakakis A; Poulos N; O'Brien-Jenkins A; Katsaros D; Butzow R; Weber BL; Coukos G
    Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5314-21. PubMed ID: 17875760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor-associated alterations in caspase-14 expression in epithelial malignancies.
    Krajewska M; Kim H; Shin E; Kennedy S; Duffy MJ; Wong YF; Marr D; Mikolajczyk J; Shabaik A; Meinhold-Heerlein I; Huang X; Banares S; Hedayat H; Reed JC; Krajewski S
    Clin Cancer Res; 2005 Aug; 11(15):5462-71. PubMed ID: 16061862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression and clinical role of antiapoptotic proteins of the bag, heat shock, and Bcl-2 families in effusions, primary tumors, and solid metastases in ovarian carcinoma.
    Elstrand MB; Kleinberg L; Kohn EC; Tropé CG; Davidson B
    Int J Gynecol Pathol; 2009 May; 28(3):211-21. PubMed ID: 19620938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ezrin promotes ovarian carcinoma cell invasion and its retained expression predicts poor prognosis in ovarian carcinoma.
    Köbel M; Gradhand E; Zeng K; Schmitt WD; Kriese K; Lantzsch T; Wolters M; Dittmer J; Strauss HG; Thomssen C; Hauptmann S
    Int J Gynecol Pathol; 2006 Apr; 25(2):121-30. PubMed ID: 16633060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular endothelial growth factor D and intratumoral lymphatics as independent prognostic factors in epithelial ovarian carcinoma.
    Li L; Liu B; Li X; Yang S; Xiao J; Chen M; Zhang Y; Ma J
    Anat Rec (Hoboken); 2009 Apr; 292(4):562-9. PubMed ID: 19226617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and evaluation of pyrido-thieno-pyrimidines as potent and selective Cdc7 kinase inhibitors.
    Zhao C; Tovar C; Yin X; Xu Q; Todorov IT; Vassilev LT; Chen L
    Bioorg Med Chem Lett; 2009 Jan; 19(2):319-23. PubMed ID: 19071019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA replication licensing factors and aurora kinases are linked to aneuploidy and clinical outcome in epithelial ovarian carcinoma.
    Kulkarni AA; Loddo M; Leo E; Rashid M; Eward KL; Fanshawe TR; Butcher J; Frost A; Ledermann JA; Williams GH; Stoeber K
    Clin Cancer Res; 2007 Oct; 13(20):6153-61. PubMed ID: 17947481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RNA interference-mediated silencing of the phosphatidylinositol 3-kinase catalytic subunit attenuates growth of human ovarian cancer cells in vitroand in vivo.
    Zhang X; Deng HX; Zhao X; Su D; Chen XC; Chen LJ; Wei YQ; Zhong Q; Li ZY; He X; Yi T
    Oncology; 2009; 77(1):22-32. PubMed ID: 19440000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of creatine kinase BB isoenzyme in epithelial ovarian carcinoma.
    Zarghami N; Katsaros D; Yu H; Diamandis EP
    Can J Oncol; 1995 Sep; 5(3):401-7. PubMed ID: 8853514
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.